Claremont Creek Ventures portfolio company AssureRx Health expands senior management team

  by on September 12th, 2011
AssureRX

It is always great to brag and cheer about one of our portfolio companies. Working with portfolio companies to help them succeed is one of a VC’s key jobs, and helping build an executive team is an area where a VC can help a lot. We are pleased to announce that AssureRx Health has just added some super people to its team. The three executives are: Dr. C. Anthony Altar, PhD, chief science officer; . . .
→ Read full post: Claremont Creek Ventures portfolio company AssureRx Health expands senior management team

Moving Quickly from an Idea to a Product

  by on July 6th, 2011

July 1, 2011  source: Genetic Engineering & Biotechnology News by Brad Webb

Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare

It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. As we point out in this article, cardiologists, psychiatrists, and internists can now order quick and inexpensive genetics-based screening . . .
→ Read full post: Moving Quickly from an Idea to a Product

Digging Deep into the Relationship of Research and Healthcare Investing

  by on September 21st, 2010

I enjoyed reading Regis Kelly’s insightful discussions about the state of academic research, and the September 14 blog post in Xconomy, The Social Contract of Science, was no exception. As the director of the California Institute for Quantitative Biosciences, the QB3 Institute, Regis enjoys a close and intimate perspective on academic research and its relation to the broader communities of government, business and society at large. I would like to broaden the conversation to . . .
→ Read full post: Digging Deep into the Relationship of Research and Healthcare Investing

Will the Stem Cell Ruling Affect Venture Capital Investing?

  by on September 1st, 2010

September 1, 2010 source: xconomy Brad Webb, Venture Partner at Claremont Creek Ventures, was featured today on the xcononomy website discussing the implications for venture investment of the recent judicial ruling regarding federal funding for stem cell research. Last week’s federal district court ruling ordering an immediate halt in federal funding for stem cell research has thrown academic research circles into a state of confusion. This has caught the attention of the VC community, . . .
→ Read full post: Will the Stem Cell Ruling Affect Venture Capital Investing?